← Back to all trials
Completed
NCT04592523
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Conditions: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase
Sex: All
Ages: 19 Years – N/A
Healthy volunteers: No
Enrollment: 271
Sponsor: Takeda
Location: Pusan National University Hospital Busan
Summary
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.
Eligibility Criteria
Inclusion Criteria:
1. With ALK-positive advanced or metastatic NSCLC.
2. Who initiate brigatinib for the first time.
Exclusion Criteria:
1. Treated with brigatinib outside of the locally approved label in Korea.
2. Whom brigatinib is contraindicated as per product label.
3. Participating in other clinical trials of NSCLC treatment.
Source: ClinicalTrials.gov (NCT04592523). StuddyBuddy aggregates publicly available trial information.
